Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661958 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 726
- Enrollment target
NCT02661958 is a Phase 2 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 726 participants.
The verdict
NCT02661958, a Phase 2 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 726 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-1
- DRUG S6G5T-5
- DRUG S6G5T-6
- DRUG S6G5T-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 726 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661958
The ClinicalTrials.gov registry entry for NCT02661958 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 726 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which S6G5T-3 is the first listed.
NCT02661958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661958 about?
NCT02661958 is a clinical study titled "Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris". The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
What is the current status of trial NCT02661958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 726 participants. The study started on 2016-05. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02661958?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-1 (DRUG), S6G5T-5 (DRUG), S6G5T-6 (DRUG), S6G5T-7 (DRUG).
Who is sponsoring clinical trial NCT02661958?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.